Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.

Abstract

The purified recombinant V antigen from Yersinia pestis, expressed in Escherichia coli and adsorbed to aluminum hydroxide, an adjuvant approved for human use, was used to immunize outbred Hsd:ND4 mice subcutaneously. Immunization protected mice from lethal bubonic and pneumonic plague caused by CO92, a wild-type F1+ strain, or by the isogenic F1- strain C12. This work demonstrates that a subunit plague vaccine formulated for human use provides significant protection against bubonic plague caused by an F1- strain (C12) or against substantial aerosol challenges from either F1+ (CO92) or F1-(C12) Y. pestis.

• Authors: G W Anderson Jr, S E Leary, E D Williamson, R W Titball, S L Welkos, P L Worsham, A M Friedlander
• Journal: Infection and immunity (Infect Immun) Vol. 64 Issue 11 Pg. 4580-5 (Nov 1996) ISSN: 0019-9567 [Print] United States
• PMID: 8890210 (Publication Type: Journal Article)

Chemical References

• Antibodies, Bacterial
• Antigens, Bacterial
• Immunoglobulin G
• LcrV protein, Yersinia
• Plague Vaccine
• Pore Forming Cytotoxic Proteins
• Vaccines, Synthetic

Topics

• Animals
• Antibodies, Bacterial (biosynthesis, blood)
• Antigens, Bacterial (immunology)
• Bacterial Capsules (analysis)
• Enzyme-Linked Immunosorbent Assay
• Female
• Immunoglobulin G (biosynthesis, blood)
• Mice
• Plague (microbiology, prevention & control)
• Plague Vaccine (immunology)
• Pore Forming Cytotoxic Proteins
• Vaccination
• Vaccines, Synthetic (immunology)
• Yersinia pestis (immunology)